Illumina (NASDAQ:ILMN) is scheduled to post its quarterly earnings results after the market closes on Monday, April 23rd. Analysts expect Illumina to post earnings of $1.04 per share for the quarter. Illumina has set its FY18 guidance at $4.50-4.60 EPS.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.22. The business had revenue of $778.00 million for the quarter, compared to analysts’ expectations of $752.04 million. Illumina had a net margin of 26.56% and a return on equity of 21.71%. The business’s revenue was up 25.7% on a year-over-year basis. During the same quarter last year, the company earned $0.85 EPS. On average, analysts expect Illumina to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Shares of NASDAQ ILMN opened at $244.60 on Friday. The company has a market cap of $36,686.40, a PE ratio of 61.15, a PEG ratio of 3.33 and a beta of 0.89. Illumina has a 12 month low of $167.98 and a 12 month high of $256.64. The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.55 and a current ratio of 3.99.
A number of equities research analysts have recently commented on the stock. BidaskClub cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, February 3rd. ValuEngine raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Canaccord Genuity reissued a “buy” rating and issued a $265.00 price target (up previously from $255.00) on shares of Illumina in a research note on Wednesday, January 31st. Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, December 26th. Finally, First Analysis raised shares of Illumina from an “equal weight” rating to an “overweight” rating and set a $277.00 price target on the stock in a research note on Wednesday, January 31st. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $243.03.
In other Illumina news, SVP Charles Dadswell sold 1,610 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $221.45, for a total value of $356,534.50. Following the transaction, the senior vice president now owns 5,581 shares in the company, valued at approximately $1,235,912.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director A Blaine Bowman sold 3,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $230.82, for a total value of $692,460.00. Following the completion of the transaction, the director now owns 19,868 shares in the company, valued at approximately $4,585,931.76. The disclosure for this sale can be found here. Insiders sold a total of 18,008 shares of company stock worth $4,130,075 in the last 90 days. 0.54% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/21/illumina-ilmn-set-to-announce-quarterly-earnings-on-monday.html.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.